

EA2183 Study

Have you been diagnosed with esophageal or gastric cancer that has spread to 1–5 places in your body? If so, you have what is called oligometastatic esophageal or gastric cancer, and you may be able to participate in this study of a potential new treatment.


Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients with Esophageal and Gastric Cancer that has Spread to a Limited Number of Other Places in the Body

WHY consider participating in this study?

- Research studies are an important way to test the effectiveness of new therapies and approaches for treating esophageal and gastric cancer.
- The usual treatment approach (the standard care most people get for oligometastatic esophageal and gastric adenocarcinoma) is treatment with a number of different Food and Drug Administration (FDA)-approved chemotherapy drugs, as well as FDA-approved immunotherapy drugs, nivolumab and pembrolizumab.
- EA2183 aims to determine 1) if **adding radiation therapy** to the usual combination of drugs used to treat your type of cancer will help you live longer, and 2) if this new approach is better or worse than the usual approach used to treat esophageal cancer or gastric adenocarcinoma.

WHAT does this study involve?

- If you decide to take part in this study, you are required to complete 3–6 months of standard treatment chosen by your doctor. If your cancer has not grown on this treatment, you will then be assigned by chance (randomized) to one of two groups:
 - Group 1: You will receive radiation therapy, then you will continue your prior standard treatment for up to 2 years.
 - » You will receive between 1–15 radiation therapy sessions, depending on the location of your cancer. You will be monitored with scans about every 2 months.
 - Group 2: You will continue to receive the standard treatment alone for up to 2 years.
 - » You will be monitored with scans about every 2 months.



EA2183 Study



- Each patient has a 2/3 chance of being in Group 1 and a 1/3 chance of being in Group 2.
- After you finish your study treatment, your doctor will continue to see you every 3 months for the first 2 years. Then, you will be seen every 6 months for up to 5 years. These post-study visits are routine clinic visits that patients with metastatic esophageal and gastric adenocarcinoma usually have.

WHO will take part in this study?

- Approximately 216 people diagnosed with oligometastatic esophageal or gastric cancer will participate in EA2183. Participants must have received 3-6 months of standard treatment and have no evidence that the cancer has gotten worse.
- You can decide to stop taking part in the study at any time, even after you have enrolled.

WHAT are the costs of taking part in this study?

- Just as you would if you were getting the usual care for your cancer, you and/or your insurance plan will need to pay for some or all of the costs of medical care you get as part of this study, including chemotherapy and radiation treatments. Check with your insurance company to find out what they will pay for.
 - Taking part in this study may mean that you need to make more visits to the clinic or hospital than if you were getting the usual treatment for your cancer.
 - You will not be paid for taking part in this study.

IF you would like to know more

- About the EA2183 study, talk with your doctor, or:
 - Visit www.ecog-acrin.org and search EA2183, then select the link to the EA2183 Home Page.
 - » If you are seeking information about the locations where the study is available, scroll down the page to Locations and Contacts and click the + sign.
 - Call the NCI Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
- About clinical trials:
 - General cancer information: visit the NCI website at www.cancer.gov
 - Insurance coverage/paying for cancer treatment: visit www.cancer.gov/clinicaltrials/learningabout/payingfor
- About ECOG-ACRIN:
 - Visit www.ecog-acrin.org
 - For a list of patient resources and links to patient advocacy groups, visit https://ecog-acrin.org/patients/resources



ECCOG-ACRIN cancer research group